Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen-Targeted Lutetium-177.

Treatment options for men with metastatic castration-resistant prostate cancer are rapidly changing. In addition to novel anti-androgens and taxane-based chemotherapy, radiopharmaceuticals are having an increasing role. Although calcium-mimetic theranostics have been in use for years, newer approaches use molecularly targeted radiation therapy by conjugating isotopes to prostate-specific membrane antigen (PSMA) and in so doing directly target prostate cancer cells; Lutetium-PSMA-617 is perhaps the best-known member of this new class.

Cell-shaped silicon-on-insulator microdosimeters: characterization and response to PuBe irradiations.

This work tested the feasibility of a silicon-on-insulator microdosimeter, which mimics the size and shape of specific cells within the human body, to determine dose equivalent from neutron irradiation. The microdosimeters were analyzed in terms of their basic diode characteristics, i.e.

Initial analysis of Pro-Qura: a multi-institutional database of prostate brachytherapy dosimetry.

Purpose: The study aimed to analyze the Pro-Qura database in terms of patient implant sequence number for each institution to determine evidence for a dosimetric learning curve.

Methods And Materials: In the Pro-Qura database, 2833 of a total of 4614 postplans from 57 brachytherapists were analyzed for evidence of a dosimetric learning curve. The median time between implant and postimplant CT scan was 30 days.